You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Virtual Bone Biopsy: Transfer to the clinical arena

    SBC: MICROMRI, INC.            Topic: N/A

    Osteoporosis is a major community health problem for which several effective FDA approved therapies exist, but which remains largely undiagnosed and untreated. While bone densitometry using dual-energy x-ray absorptiometry (DXA) is the current "gold standard" in osteoporosis diagnosis, controlled clinical trials have highlighted its sensitivity and specificity limitations at the individual patient ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Low Antigenicity Factor VIII

    SBC: Octagen Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Octagen's broad, long-term objective is to complete the clinical development and secure FDA approval of its b-domain deleted recombinant factor VIII (OBI-1), a low antigenicity version of factor VIM (fVIII). OBI-1 is designed for the treatment of patients with inhibitory, neutralizing antibodies to human fVIII. Such "inhibitor" patients include congenital hemop ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Cross-enterprise access to cancer imaging data

    SBC: Hx Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to launch the first commercial service enabling physicians at unaffiliated hospitals to directly retrieve their patients' digital images and reports from each other on-demand. Despite significant societal need and market demand, US hospitals remain islands of mutually inaccessible data even as patients move between them. Even the most vulnerable p ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Synthesis and Evaluation of a Novel Anti-HIV Agent

    SBC: Kucera Pharmaceutical Company            Topic: N/A

    The long-term goal of this research is to develop a drug that is safe and effective against drug-resistant human immunodeficiency virus (HIV) infection. Several challenges confront current anti-HIV chemotherapy. The frequency of drug-resistant and multidrug-resistant HIV-1 is increasing. Toxicities associated with current HIV medications often result in the discontinuation of these therapies. Phys ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Phototoxicity Screening Assay in Reconstituted Skin

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed and prevalidated an in vitro screening test for phototoxicity, the Enhanced Phototoxicity Assay in Reconstituted Skin (EPARS), to replace the current standard animal phototoxicity tests. The phototoxic potential of chemicals, cosmetics, dietary supplements and Pharmaceuticals are a major and growing concern in the consumer products industry, b ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. SUMO fusion for genome-wide protein analysis

    SBC: LIFESENSORS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): A vast number of novel proteins discovered from genome sequencing projects are creating enormous opportunities for scientists in academia and industry. Large-scale consortia and initiatives are underway to understand the structures of newly discovered proteins. Unfortunately, protein expression and purification are a major bottleneck. Bacteria are usually th ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Diabetic Foot Ulcer Healing by Load Relieving Dressings

    SBC: DIAPEDIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In the US more than 80,000 lower extremity amputations are performed in diabetic patients per year. Foot ulcers are much more common and the path to most amputations starts with an ulcer. The health care cost of these problems has been estimated to be almost $11 billion per year. The longer an ulcer stays open, the more likely it is to get infected and lead to ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. A cell-free system for assaying ion channel function

    SBC: INTEGRAL MOLECULAR, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Ion channels function as cell-signaling effectors for a diverse range of physiological activities, including nerve signal propagation, muscle contraction, cardiopulmonary regulation, and cell metabolism. Their impact on human health is underscored by the existence of forty compounds, including about 15% of the top 100 best-selling drugs, that target ion channe ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Gene Expression in Circulating Tumor Cells

    SBC: Immunicon Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The informed development of new treatments for cancer would be greatly facilitated if tumor cells could be directly sampled at multiple time points following the administration of new drugs or drug combinations. Many new agents are not classic cytotoxics, but specifically target tumor cell biological processes or elements of the tumor stroma. In many cases, th ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government